ERBB2 and non-small cell lung carcinoma: These guidelines recommend routine multigene testing of all advanced NSCLC with an adenocarcinoma component for EGFR mutations and ALK and ROS1 rearrangements, together with additional genes (RET, MET, Her2, KRAS, and BRAF).